Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02370576
Other study ID # rambam001
Secondary ID
Status Not yet recruiting
Phase N/A
First received February 15, 2015
Last updated February 24, 2015
Start date March 2015
Est. completion date March 2018

Study information

Verified date February 2015
Source Rambam Health Care Campus
Contact Marina Bar-Shai, MD, PhD
Phone 972-50-2062142
Email m_bar-shai@rambam.health.gov.il
Is FDA regulated No
Health authority Israel: The Israel National Institute for Health Policy Research and Health Services Research
Study type Observational [Patient Registry]

Clinical Trial Summary

Determination of incidence and prevalence of PTSD and other types of psychopathology (such as anxiety and affective disorders) after traumatic birth experiences and elucidation of salient risk factors in the local population sample- by prospective follow-up.


Description:

Post- traumatic stress disorder (PTSD)- definitions The criteria for the diagnosis of traumatic experience involve the experience of a specific traumatic stressor and, subsequently, four axes of symptoms: (i) re-experiencing of the traumatic event, including nightmares, intrusive thoughts and emotions; (ii) avoidance of stimuli associated with the traumatic event; (iii) hyperarousal, expressed as difficulties sleeping or concentrating, irritability, enhanced startle responses, irritable, aggressive, reckless or self-destructive behavior and (iv) persistent negative alterations in cognitions and mood. Formal clinical diagnosis of PTSD can only be made after symptoms have been present for at least 1 month. The definition of a traumatic event includes the witnessing or experience of serious threat to life or bodily integrity, or injury (either physical or emotional) to oneself or others [1]. As such, the subjective and objective experience of giving birth became recognized as a possibly traumatic event for some women [2]. As a result of a traumatic childbirth, women may experience general distress, flashbacks, dissociation, amnesia, sleep disturbances, negative evaluation of self-worth, difficulty breastfeeding, relationship problems and problems with their own sexuality [3-7], problems with bonding with their infants [8-12], or significant fear of subsequent childbirth (tocophobia); many choose not to conceive again for this reason. The afflicted women that do choose to have further children may insist on a cesarean delivery in hopes that it will not be as traumatic [6].

PTSD after childbirth- prevalence, risk factors, clinical characteristics and long term implications About 2- 6% of women will experience the full DSM-V criteria for PTSD at some point after giving birth [13-14]. An additional 22- 40% may meet the criteria for subsyndromal PTSD, and another 20-50% of women may report the childbirth experience as traumatic [13-14].

It is not known at this point what are the characteristics of women who may develop postpartum PTSD, making it impossible to predict or to prevent this outcome. However, several risk factors have been recently elucidated. Several predisposing/prenatal factors associated with the childbirth experience itself have been associated with PTSD. These include previous psychiatric history [15, 16, 17,18] (especially depression in pregnancy), socio-demographic problems [19,20, 21] (lack of support, problematic relationship with the partner), parity (primiparous more at risk), personality traits and disorders [22 -24] (trait anxiety; anxiety sensitivity, neuroticism), previous trauma [25-26]

- previous childbirth-related trauma; sexual abuse), maladaptive cognitions [27] (pre-existing, maladaptive schemas; negative cognitive appraisal of past childbirth; autobiographical memory specificity, fear of upcoming childbirth), nature of delivery [28, 29] (type and number of interventions; duration, fear of harm to self or baby, emergency cesarean section (CS), instrumental delivery- especially forceps- assisted, episiotomy), perception of care from medical staff [24, 29], perception of loss of control [24, 30], perception of pain [24 ], infant complications [28-29] (especially low birth weight, low Apgar score, asphyxia, resuscitation, prematurity), and peritraumatic dissociation [31-32] - feeling of unreality; alterations in perception of time and place; feeling of disconnection from body). Women having unplanned caesarean section births were likely to report PTSD-type symptoms. However, there was no association between PTSD type symptoms and planned caesarean section births [16, 33]. PTSD is also associated with preeclampsia [34-35]. Preeclampsia is associated with both maternal complications (e.g. eclampsia, abruptio placentae, pulmonary edema, acute renal failure) [36-37], and perinatal complications (e.g. fetal growth restriction, preterm delivery, and perinatal death) [38, 39-40]. As previously described, these adverse pregnancy outcomes are known to be associated with PTSD [41, 43, 44 -46]. Other seemingly routine aspects of pregnancy may increase vulnerability to active PTSD, especially in victims childhood sexual trauma or intrafamilial abuse [47, 48, 3-4], previous pregnancy loss [5,6 ] or prior traumatic birth [7], or when pregnancy is a result of sexual assault. Inherent physical aspects of pregnancy such as increased breast sensitivity and fetal movement are potentially triggering. Routine aspects of prenatal care, including vaginal and breast examinations, can be triggers, especially for sexual trauma survivors. Labor itself, especially medicalised labor can exacerbate a sense of powerlessness and vulnerability, which can trigger PTSD symptoms [49]. Physical changes of pregnancy, especially cardiovascular, respiratory, gastrointestinal and renal system alterations, also could affect the experience of PTSD symptoms [49], since they might resemble physical sensations associated with anxiety.

It is unclear whether traumatic birth experiences can lead to other types of psychopathology, such as postpartum depression or anxiety disorders, and more research is needed to answer this question. However, since there is a known association between traumatic experiences and affective and anxiety disorders in general- one can surmise that this association exists also between these disorders and traumatic birth experiences [10, 12, 16].

It is now believed that PTSD severity after childbirth reaches a plateau over the 12 months postpartum, without further improvement, which means that women with postpartum PTSD do not spontaneously recover [50]. Thus, many afflicted women develop a chronic disorder that significantly interferes with their functioning in various areas of life. PTSD during the postpartum period is an important public health issue because of the longer-term negative impact of maternal mental health problems on child development [8] including impaired mother-infant relationship [9-10], delayed intellectual development [11,12 ], and psychiatric disorder in children [51]. In many PTSD patients the baby can become a constant reminder of the traumatic birth. Some women report that they felt guilty for blaming the baby after a traumatic childbirth experience. PTSD within 11 months postpartum is associated with depression within 11 months postpartum. Little is known about mother-child bonding in women with PTSD after childbirth, while the negative impact of maternal postnatal depression on child development has been investigated by different authors showing that especially chronicity of maternal depression after birth is a predictor for negative development [28, 12].

PTSD after childbirth- pathophysiology Pregnancy is associated with alterations in the hypothalamic-pituitary-ovarian (HPO) axis, particularly increases in plasma concentrations of progesterone and estrogen, which can modulate mood and cognition. Pregnancy also is associated with changes in the hypothalamic-pituitary-adrenal (HPA) axis, including increases in plasma adrenocorticotropic hormone and cortisol, and a large increase in plasma corticotropin-releasing hormone, especially in the third trimester (from placental secretion) [16].

In addition to being a stress hormone, cortisol appears to affect memory, salience, social cognition, negative mood, [52] alertness and sleep [52]. It is possible that the altered hormonal milieu of both HPA and HPO axes in pregnancy could affect the expression of PTSD symptoms by increasing frequency and emotional intensity of traumatic memories, which in turn affect mood, motivation, social cognition, sleep, and concentration [33].

PTSD after childbirth- assessment tools. Several validated rating scales are in use in PTSD research. The gold standard is Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), which is rated by a researcher and necessitates time and experience in its administration. PTSD Symptoms Scale (PSS) and PTSD Checklist for DSM-5 (PCL-5) are self- report short rating scales. Also in use are depression rating scales such as Montgomery- Asberg Depression Rating Scale (MADRS, researcher- administered), Major Depression Inventory (MDI, self- report) and Edingurgh Postnatal Depression Scale (EPDS, self- report, specifically created to assess the symptoms of peri- and postpartum depression) [53].

Research goals. Determination of incidence and prevalence of PTSD and other types of psychopathology (such as anxiety and affective disorders) after traumatic birth experiences and elucidation of salient risk factors in the local population sample- by prospective follow-up.

Materials and methods We shall apply to the local Helsinki Committee to receive the approval for the research. The participants will receive an explanation and sign informed consent.

Compare a cohort of women with perinatal complications (emergency CS, instrumental deliveries, premature labor, serious hemorrhage at childbirth, perineal tear that required stitching, resuscitation of the newborn, newborn admitted to neonatal intensive care unit) to a control cohort of healthy women who delivered by elective uncomplicated CS. For women in both cohorts it should be their first pregnancy and first childbirth. Assess with the help of rating scales (both researcher- administered and self- report, such as CAPS, PCL-C, MADRS, MDI, EPDS) in the first two days following childbirth to measure the baseline parameters and to assess the prevalence of acute stress reaction (ASR) in the research and the control cohorts. Assess again both cohorts by the above methods 1 month after childbirth. Compare the prevalence of PTSD between the different cohorts of perinatal complications and the control cohort. Also- compare the prevalence of PTSD, anxiety and mood disorders between the different groups of perinatal complications in order to determine which type of complication carries the greater risk for the development of psychopathology. Determine whether the development of ASR 2 days after childbirth is predictive of PTSD and other types of psychopathology 1 month after childbirth. Thus- determine the prevalence of PTSD and other types of psychopathology 1 month after birth in risk groups versus controls, prospectively.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 500
Est. completion date March 2018
Est. primary completion date March 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- No psychiatric background

Exclusion Criteria:

- Known psychiatric disorder

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Other:
rating scale application
Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum. rating scale application

Locations

Country Name City State
Israel Rambam Medical Center Haifa

Sponsors (1)

Lead Sponsor Collaborator
Rambam Health Care Campus

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Presence or absence of PTSD (Questionnaire/ rating scale application) 1 month No
Secondary Presence or absence of major depression (Questionnaire/ rating scale application) 1 month No
Secondary Presence or absence of anxiety disorders (Questionnaire/ rating scale application) 1 month No
See also
  Status Clinical Trial Phase
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT05415397 - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs Phase 3
Recruiting NCT05988333 - Psychoeducational Intervention for Families With a Member Affected by Major Depression N/A
Completed NCT02919501 - Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder Phase 2
Completed NCT00976560 - Clinical Study to Test a New Drug to Treat Major Depression Phase 2
Recruiting NCT05518149 - A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) Phase 3
Not yet recruiting NCT06303076 - Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial Phase 4
Not yet recruiting NCT05901571 - Acupuncture and Escitalopram for Treating Major Depression Clinical Study N/A
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Suspended NCT02546024 - Predictors of Treatment Response in Late-onset Major Depressive Disorder N/A
Completed NCT01407575 - Buprenorphine for Treatment Resistant Depression Phase 3
Completed NCT01583400 - Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial N/A
Completed NCT01152996 - Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study Phase 3
Enrolling by invitation NCT00762866 - Psychiatric Genotype/Phenotype Project Repository
Completed NCT00366652 - Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects Phase 3
Completed NCT00369343 - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women Phase 3
Completed NCT00384033 - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder Phase 3
Completed NCT00149643 - Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence Phase 2
Completed NCT00316160 - Sexual Functioning Study With Antidepressants Phase 4